O-020 Quality-of-life results from RAISE: randomized, double-blind phase III study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal carcinoma after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine

First Line ◽

Double Blind ◽

First Line Therapy ◽

Line Therapy ◽

Quality-of-life (QoL) results from RAINFALL: A randomized, double-blind, placebo (PL)-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy for metastatic gastric or gastroesophageal junction (G-GEJ) cancer

Annals of Oncology ◽

10.1093/annonc/mdy282.001 ◽

2018 ◽

Vol 29 ◽

pp. viii205-viii206

Author(s):

I. Chau ◽

S.-E. Al-Batran ◽

A. Luft ◽

R.D. Kowalyszyn ◽

C.A. Hernandez ◽

...

Keyword(s):

Quality Of Life ◽

Gastroesophageal Junction ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.lba1011 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. LBA1011-LBA1011 ◽

Cited By ~ 87

Author(s):

D. Miles ◽

A. Chan ◽

G. Romieu ◽

L. Y. Dirix ◽

J. Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study ◽

Locally Recurrent

2108 Subgroup analysis by KRAS status in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression during or following first-line combination therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine

European Journal of Cancer ◽

10.1016/s0959-8049(16)31030-9 ◽

2015 ◽

Vol 51 ◽

pp. S365

Author(s):

E. Van Cutsem ◽

R. Obermannova ◽

G. Bodoky ◽

J. Prausová ◽

R. García-Carbonero ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Combination Therapy ◽

Folinic Acid ◽

Subgroup Analysis ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Kras Status ◽

Review of RAISE, a Randomized, Double-Blind, Multicenter Phase III Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (RAM) or Placebo (PBO) in Patients (pts) With Metastatic Colorectal Carcinoma (mCRC) Progressive During or Following First-Line Combination Therapy With Bevacizumab (bev), Oxaliplatin (ox), and a Fluoropyrimidine (fp): Primary Results and Subgroup Analysis by KRAS Status

Annals of Oncology ◽

10.1093/annonc/mdv340.05 ◽

2015 ◽

Vol 26 ◽

pp. vi37 ◽

Cited By ~ 2

Author(s):

A. Sobrero ◽

L. Latini ◽

C. Barone ◽

F. Capuzzo ◽

M. Banzi ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Combination Therapy ◽

Subgroup Analysis ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Multicenter Phase ◽

Kras Status ◽

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Yearbook of Oncology ◽

10.1016/j.yonc.2012.05.013 ◽

2012 ◽

Vol 2012 ◽

pp. 138-139 ◽

Cited By ~ 1

Author(s):

E.G. Chiorean

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophogeal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps4131 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS4131-TPS4131 ◽

Cited By ~ 4

Author(s):

Charles S. Fuchs ◽

Josep Tabernero ◽

Salah-Eddin Al-Batran ◽

Ian Chau ◽

David H. Ilson ◽

...

Keyword(s):

Phase Iii ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)70127-0 ◽

2015 ◽

Vol 16 (5) ◽

pp. 499-508 ◽

Cited By ~ 406

Author(s):

Josep Tabernero ◽

Takayuki Yoshino ◽

Allen Lee Cohn ◽

Radka Obermannova ◽

Gyorgy Bodoky ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Second Line ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

First Line Therapy ◽

Line Therapy

197TiP A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859

Annals of Oncology ◽

10.1016/j.annonc.2020.10.461 ◽

2020 ◽

Vol 31 ◽

pp. S1316-S1317

Author(s):

S. Qin ◽

J. Tabernero ◽

E. van Cutsem ◽

C.S. Fuchs ◽

Y.Y. Janjigian ◽

...

Keyword(s):

Gastroesophageal Junction ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

First Line Therapy ◽

Line Therapy ◽

94P Patient-reported outcomes (PROs) following sintilimab (sint) plus pemetrexed (pem) and platinum (plt) based chemotherapy as first-line therapy for locally advanced or metastatic nonsquamous NSCLC: A randomized, double-blind, phase III study (Orient-11)

Annals of Oncology ◽

10.1016/j.annonc.2021.10.112 ◽

2021 ◽

Vol 32 ◽

pp. S1415

Author(s):

J. Fang ◽

Y. Zhao ◽

B. Han ◽

G. Chen ◽

Z. Yang ◽

...

Keyword(s):

Patient Reported Outcomes ◽

Locally Advanced ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

First Line Therapy ◽

Line Therapy ◽

Patient Reported ◽

Phase Iii Study ◽

Nonsquamous Nsclc

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

ESMO Open ◽

10.1016/j.esmoop.2021.100062 ◽

2021 ◽

Vol 6 (2) ◽

pp. 100062

Author(s):

J. Sastre ◽

P. García-Alfonso ◽

J.M. Viéitez ◽

M.T. Cano ◽

F. Rivera ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Phase Ii ◽

Tumour Cells ◽

Circulating Tumour Cells ◽

Wild Type ◽

First Line ◽

Pik3ca Mutations ◽

First Line Therapy ◽

Line Therapy